Tetraxim^® is a tetravalent adjuvanted combined vaccine which is indicated to protect child against diphtheria, pertussis, tetanus and poliomyelitis for primary vaccination from the age of 2 months in infants and for booster vaccination during the second year of life, between 5 and 13 years of age, according to the national official recommendations. It works by developing immunity by initiation of mild infection. This type of infection does not cause illness but helps to stimulate body immune system to produce antibodies to protect against any future infections.

Tetraxim^® is a single injection vaccine that offers primary advantages and also provides polio vaccination coverage as high as that for 3 doses of DTaP vaccine. Tetraxim^® is a liquid combination of diphtheria, tetanus, acellular pertussis, and inactivated polio virus vaccine (DTaP-IPV) which has been licensed since 1997 in more than 70 countries.¹

Clinical trials data of Tetraxim^® vaccine exhibited high immunogenicity against all antigens when administered at 2, 4, and 6 months of age in infants.¹

Tetraxim^® vaccine is a well-established product. The manufacturing process is validated adequately with appropriate in-process and quality control checks. The manufacturing and quality standards ensure safety and efficacy of the product.